May 09,2022

The Influence of Real-Time Continuous Glucose Monitoring on Psychosocial Outcomes in Insulin-Using Type 2 Diabetes

The study examines the impact of real-time continuous glucose monitoring (rtCGM) on psychosocial outcomes in adults with insulin-using type 2 diabetes (T2D).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 13,2022

Laboratory Protocol and Pilot Results for Dynamic Interference Testing of Continuous Glucose Monitoring Sensors

Testing the potential influence of interfering substances on the measurement performance of needle sensors for continuous glucose monitoring (CGM) is a challenging task. For proper function, the sensors need an almost stable fluidic environment.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 16,2022

Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan

Terumo Corporation (TSE: 4543) today announces that the indication for the Dexcom G6 CGM System has changed in Japan as of May 10, 2022. With this new indication, the Dexcom G6 CGM System will be the only real-time continuous glucose monitoring system (RT-CGM) in Japan that can be used principally for day-to-day management of blood glucose levels without the adjunctive use of a blood glucose meter. Terumo holds the exclusive distribution agreement rights to distribute this product in Japan, and it has been available for Japanese patients with diabetes since 2021.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 01,2022

Commencement of flash glucose monitoring is associated with a decreased rate of depressive disorders among persons with diabetes (FLARE-NL7)

This study aims to assess the effects of commencement of FreeStyle Libre flash glucose monitoring (FSL-FGM) on the mental health status of persons with diabetes.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 01,2022

Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), announced today that people with type 1 and type 2 diabetes age two and over on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System through Prince Edward Island’s Diabetes Glucose Sensor Program.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 03,2022

ABBOTT ANNOUNCES DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE-KETONE MONITORING SYSTEM

Abbott (NYSE: ABT) today announced it's developing a new biowearable that will continuously monitor glucose and ketone levels in one sensor. The system has secured breakthrough device designation from the U.S. Food and Drug Administration, which is designed to expedite the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 04,2022

One Drop Study Signals Significant Growing Interest in Continuous Glucose Monitors (CGMs) Among People with Type 2 Diabetes

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, presented new research at the 82nd Scientific Sessions of the American Diabetes Association on attitudes and adoption of continuous glucose monitors (CGM) among people with type 2 diabetes (T2D).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 04,2022

Health Care Professionals’ Perspectives on Use of Diabetes Technologies for Managing Visually Impaired Patients With Diabetes

The study aimed to identify providers’ preferences and challenges to prescribing diabetes technologies for visually impaired patients.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 04,2022

Neural Networks With Gated Recurrent Units Reduce Glucose Forecasting Error due to Changes in Sensor Location

Recently, neural networks (NNs) have become a common method for forecasting glucose values using data from CGMs. One method of forecasting glucose values is a time-delay feedforward (FF) NN, but a change in the CGM location on a participant can increase forecast error in a FF NN.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 05,2022

LATE-BREAKING DATA DEMONSTRATE ABBOTT'S FREESTYLE LIBRE® 3 SYSTEM IS MOST ACCURATE 14-DAY CONTINUOUS GLUCOSE MONITOR

Abbott (NYSE: ABT) today announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute relative difference (MARD) of 7.9%,1 making it the first and only 14-day continuous glucose monitoring (CGM) system to achieve a sub-8% overall MARD.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM